<DOC>
	<DOCNO>NCT00845988</DOCNO>
	<brief_summary>The primary goal study investigate metabolic change maintain efficacy stabilize patient bipolar disorder pharmacologically induce weight gain .</brief_summary>
	<brief_title>Metabolic Effects Switching Aripiprazole Patients With Bipolar Disorders</brief_title>
	<detailed_description>- reduce treatment adherence due metabolic side effect - suggest advantage aripiprazole metabolic profile antipsychotic mood stabilizer - randomize trial switch previous drug aripiprazole</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>patient bipolar disorder ( I , II , NOS ) diagnose DSMIV criterion age 18 65 Decisional capacity adequate provide inform consent authorize appropriate surrogate decision maker . syndromal remission state least 2 month : CGI BP â‰¤ 3 patient exhibit clinically significant increase body weight start administration current antipsychotic ( ie &gt; 7 % weight gain ) diagnosis eat disorder , substance abuse , psychotic disorder history neurological medical illness pregnant breast feeding woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>metabolic complication</keyword>
	<keyword>Aripiprazole</keyword>
	<keyword>Weight gain</keyword>
	<keyword>Clinical Trial</keyword>
	<keyword>Antipsychotic</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Psychopharmacology</keyword>
	<keyword>Open Label</keyword>
</DOC>